Hector Moreno-Garcia

UCL Queen Square Institute Of Neurology
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Cognitive impairment in SCA3: A multi-center cohort study with demographic, imaging, and biomarker correlates.

Cognitive impairment in SCA3: A multi-center cohort study with demographic, imaging, and biomarker correlates.

Journal: Neurobiology of disease

Published: November 05, 2025

Role of Repeat Tract Structure and the rs7158733 SNP in Spinocerebellar Ataxia 3.

Role of Repeat Tract Structure and the rs7158733 SNP in Spinocerebellar Ataxia 3.

Journal: International journal of molecular sciences

Published: August 12, 2025

An Exploration of Vitamin D Deficiency and Clinical Status in Friedreich's Ataxia Patients in the UK.

An Exploration of Vitamin D Deficiency and Clinical Status in Friedreich's Ataxia Patients in the UK.

Journal: Movement disorders clinical practice

Published: July 30, 2025

Remote Assessment of Ataxia Severity in SCA3 Across Multiple Centers and Time Points.

Remote Assessment of Ataxia Severity in SCA3 Across Multiple Centers and Time Points.

Journal: Annals of clinical and translational neurology

Published: July 29, 2025

Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment.

Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment.

Journal: EBioMedicine

Published: June 30, 2025

Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis.

Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis.

Journal: Acta neuropathologica communications

Published: June 24, 2025

The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI Cohort.

The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI Cohort.

Journal: CNS drugs

Published: April 26, 2025

Progression of biological markers in spinocerebellar ataxia type 3: analysis of longitudinal data from the ESMI cohort.

Progression of biological markers in spinocerebellar ataxia type 3: analysis of longitudinal data from the ESMI cohort.

Journal: medRxiv : the preprint server for health sciences

Published: February 20, 2025

Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort.

Progression of biological markers in spinocerebellar ataxia type 3: longitudinal analysis of prospective data from the ESMI cohort.

Journal: The Lancet regional health. Europe

Published: February 01, 2025

Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology.

Increase of Plasma Biomarkers in Friedreich's Ataxia: Potential Insights into Disease Pathology.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 02, 2024

GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice.

GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice.

Journal: Journal of neurology

Published: September 16, 2024

Regional distribution of polymorphisms associated to the disease-causing gene of spinocerebellar ataxia type 3.

Regional distribution of polymorphisms associated to the disease-causing gene of spinocerebellar ataxia type 3.

Journal: Journal of neurology

Published: September 05, 2024

Showing 1-12 of 53

Last Updated: 09/26/2026